UFC flyweight Alibi Idiris accepted a one-year suspension after testing positive for hydrochlorothiazide, a banned diuretic, in an in-competition sample collected during fight week in Houston. The UFC and Combat Sports Anti-Doping said the substance was used to help him make the contracted weight for his most recent fight. The suspension began on 2026-02-21 and is scheduled to run through 2027-02-21. The development matters because it affects his availability and is expected to lead to his previous win being changed to a no-contest.
UFC flyweight Alibi Idiris has accepted a one-year anti-doping suspension after testing positive for hydrochlorothiazide, a banned diuretic, in an in-competition sample collected during fight week in Houston. The suspension took effect on February 21, 2026, and is set to run through February 21, 2027. According to the UFC and Combat Sports Anti-Doping, the substance was used to assist Idiris in making his contracted weight ahead of his most recent bout.
Idiris, 31, carries a professional record of 12-1-0 and competes in the UFC's flyweight division. The Orthodox-stance fighter stands five-foot-six with a 68-inch reach and has built his reputation largely on a wrestling-heavy approach, averaging 3.25 takedowns per 15 minutes. He lands 2.51 significant strikes per minute at a 44 percent accuracy rate. The suspension sidelines one of the division's more active and well-rounded competitors at what should be a productive stage of his career.
Why it matters
- Idiris will be unavailable until February 2027, removing him from flyweight contention for roughly the next eight months.
- His previous win is expected to be overturned to a no-contest, altering the official record of both fighters involved in that bout.
- The case highlights ongoing weight-management pressures at flyweight, where the cut to 125 pounds pushes athletes toward drastic measures.
- The ruling comes through a formal acceptance rather than a contested hearing, suggesting Idiris and his team did not dispute the findings.
